Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Fig. 3 | Breast Cancer Research

Fig. 3

From: Radiomic signatures with contrast-enhanced magnetic resonance imaging for the assessment of breast cancer receptor status and molecular subtypes: initial results

Fig. 3

Top: contrast-enhanced fat-saturated T1-weighted image of a 50-year-old patient with a HER2-enriched cancer in the left breast. Bottom: contrast-enhanced T1-weighted image of a 59-year-old patient with a triple-negative cancer in the right breast. Both lesions are irregularly shaped and margined, with heterogeneous contrast enhancement and central necrosis. Radiomic signatures derived from contrast-enhanced MRI (CE-MRI) accurately differentiated HER2-enriched from triple-negative breast cancer with an overall accuracy of 73.5% in our patient collective

Back to article page